3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
19
Neoplasm Metastasis
5
Triple Negative Breast Neoplasms
3
Brain Neoplasms
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
HER2-positive Breast Cancer
2
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Solid Tumor
1
Recurrence
1
Rare Tumour
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Ovarian Neoplasms
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Meningioma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Interventions
Carboplatin
5
pembrolizumab
4
Trastuzumab
4
Oxaliplatin
4
Fluorouracil
4
Cyclophosphamide
4
Radiotherapy
3
Paclitaxel
3
Endoscopy
3
Docetaxel
3
Cytarabine
3
Chemoradiotherapy
3
Capecitabine
3
toripalimab
2
Tretinoin
2
Surgical Procedures, Operative
2
Standard of Care
2
Observation
2
Neoadjuvant Therapy
2
Metformin
2
Magnetic Resonance Imaging
2
Leucovorin
2
Irinotecan
2
Immunotherapy
2
Immune Checkpoint Inhibitors
2
Epirubicin
2
Drug Therapy
2
Doxorubicin
2
Cisplatin
2
Blood Specimen Collection
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Pathologic Complete Response
×
neratinib
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled